Back to School: How biopharma can reboot drug development. Access exclusive analysis here
DRI will provide C$1.5 million to further TPL's development of paclitaxel, a naturally occurring cancer compound
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury